Serum microRNA-135a downregulation as a prognostic marker of non-small cell lung cancer.

Abnormal expression of microRNA-135a (miR-135a) is closely associated with oncogenesis. However, the relationship between serum miR-135a levels and the clinical parameters and prognosis of non-small cell lung cancer (NSCLC) remain unclear. The study aimed to investigate the clinical significance of serum miR-135a expression in patients with NSCLC. miR-135a expression was analyzed by real-time PCR and its correlation with NSCLC was determined by various statistical methods for 104 NSCLC patients and 40 healthy volunteers. The serum miR-135a level was significantly lower in NSCLC patients than in healthy control subjects (P < 0.01), and was closely related to distant metastasis (P < 0.015), lymphatic metastasis (P = 0.000), TNM (tumor node metastasis) stage (P = 0.001), and pathological stage (P = 0.021) of NSCLC. The five year overall survival was significantly lower in patients with low miR-135a expression than that in patients with high serum miR-135a levels (P = 0.010). Multivariate analysis showed that serum miR-135a level could be treated as an independent risk factor for NSCLC prognosis (P = 0.011). In conclusion, the serum miR-135a level was downregulated in NSCLC patients, and was associated with poor prognosis. Additionally, it can be used as a biomarker for NSCLC prognosis.

Structural and biochemical characteristics of chitin-binding protein SeCBP66 from Spodoptera exigua (Hübner).

Peritrophic membrane proteins are important components of the insect peritrophic membrane. A novel cDNA gene encoding a chitin-binding protein, named secbp66, was identified by immunization screening of the cDNA library of Spodoptera exigua. The full length of secbp66 is 1806 bp, which encodes 602 amino acids. The predicted weight of the protein is 64.2 kDa. Bioinformatic analysis showed that a signal peptide composed of 17 amino acids located at the N-terminal of SeCBP66 contained seven tandem putative Type-II functional chitin-binding domains and five potential N-glycosylation sites, but no O-linked glycosylation sites. To study the properties of SeCBP66, recombinant SeCBP66 was successfully expressed in the insect cell line BTI-Tn-5B1-4 with a Bac-to-Bac expression system. A chitin binding experiment showed that the recombinant SeCBP66 protein could bind to chitin strongly. This study of the novel chitin-binding protein SeCBP66 provides a basis for developing new control targets for S. exigua.

Effect of Ginkgo biloba extract on matrix metalloproteinase-3 expression in a rat model of chondrocyte injury.

A rat model with cartilage chondrocyte injury was established using interleukin-1ß (IL-1ß) to investigate the effect of Ginkgo biloba extract (EGb) on matrix metalloproteinase-3 (MMP-3) expression. Rat chondrocytes were extracted and randomly divided into six groups: control group, IL-1ß (model) group, IL-1ß + dexamethasone group, and IL-1ß + EGb group (both high and low dose groups). Reverse transcriptase polymerase chain reaction and enzyme-linked immunosorbent assay were used to detect MMP-3 expression. Compared to the MMP-3 mRNA level in the control group, MMP-3 mRNA level significantly increased in the model group (P < 0.05). The application of dexamethasone or EGb significantly decreased the MMP-3 mRNA level (P < 0.05). MMP-3 mRNA and protein levels decreased in the EGb-treated group, especially in the high-dose group, compared to those in the dexamethasone group (P < 0.05). EGb may reduce MMP-3 production during IL-1ß-induced chondrocyte damage and protect chondrocytes to some extent, with better efficacy at high doses.